Header Logo

Connection

GEORGE R BLUMENSCHEIN to Prognosis

Back to Details
This is a "connection" page, showing publications GEORGE R BLUMENSCHEIN has written about Prognosis.
GEORGE R BLUMENSCHEIN
Connection Strength
0.352
Prognosis
  1. Phase II study of gefitinib in patients with advanced salivary gland cancers. Head Neck. 2015 May; 37(5):644-9.
    View in: PubMed
    Score: 0.035
  2. Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study. J Thorac Oncol. 2012 Sep; 7(9):1406-16.
    View in: PubMed
    Score: 0.029
  3. Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs. 2013 Apr; 31(2):417-24.
    View in: PubMed
    Score: 0.029
  4. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer. 2013 Jan 01; 119(1):7-15.
    View in: PubMed
    Score: 0.029
  5. Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. J Clin Oncol. 2022 03 01; 40(7):702-709.
    View in: PubMed
    Score: 0.014
  6. Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck. Head Neck. 2021 05; 43(5):1592-1603.
    View in: PubMed
    Score: 0.013
  7. Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer. J Thorac Oncol. 2019 11; 14(11):1901-1911.
    View in: PubMed
    Score: 0.012
  8. Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. Clin Cancer Res. 2018 06 15; 24(12):2771-2779.
    View in: PubMed
    Score: 0.011
  9. A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced?Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 03; 12(3):556-566.
    View in: PubMed
    Score: 0.010
  10. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget. 2016 Apr 26; 7(17):23227-38.
    View in: PubMed
    Score: 0.009
  11. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2015 Jul; 26(7):1476-80.
    View in: PubMed
    Score: 0.009
  12. Time to treatment as a quality metric in lung cancer: Staging studies, time to treatment, and patient survival. Radiother Oncol. 2015 May; 115(2):257-63.
    View in: PubMed
    Score: 0.009
  13. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015 Feb; 16(2):187-99.
    View in: PubMed
    Score: 0.009
  14. EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324. Radiother Oncol. 2014 Jul; 112(1):30-6.
    View in: PubMed
    Score: 0.008
  15. Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy. J Clin Oncol. 2016 Feb 10; 34(5):e34-7.
    View in: PubMed
    Score: 0.008
  16. Mesothelin expression and survival outcomes in triple receptor negative breast cancer. Clin Breast Cancer. 2013 Oct; 13(5):378-84.
    View in: PubMed
    Score: 0.008
  17. Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. J Thorac Oncol. 2013 Apr; 8(4):436-42.
    View in: PubMed
    Score: 0.008
  18. Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J Thorac Oncol. 2012 Nov; 7(11):1645-52.
    View in: PubMed
    Score: 0.007
  19. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res. 2012 Apr 15; 18(8):2269-77.
    View in: PubMed
    Score: 0.007
  20. Phase II trial of induction chemotherapy followed by surgery for squamous cell carcinoma of the oral tongue in young adults. Head Neck. 2012 Sep; 34(9):1255-62.
    View in: PubMed
    Score: 0.007
  21. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients. Am J Surg Pathol. 2007 Nov; 31(11):1645-52.
    View in: PubMed
    Score: 0.005
  22. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. Int J Radiat Oncol Biol Phys. 2007 Jul 01; 68(3):779-85.
    View in: PubMed
    Score: 0.005
  23. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer. 2006 Mar; 7(5):326-31.
    View in: PubMed
    Score: 0.005
  24. Breast cancer. Cancer Treat Rev. 1984 Dec; 11(4):315-9.
    View in: PubMed
    Score: 0.004
  25. Significance of drug dose, timing and radiotherapy in adjuvant therapy of breast cancer. Recent Results Cancer Res. 1984; 96:141-7.
    View in: PubMed
    Score: 0.004
  26. The role of progestins in the treatment of breast cancer. Semin Oncol. 1983 Dec; 10(4 Suppl 4):7-10.
    View in: PubMed
    Score: 0.004
  27. Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol. 1983 Dec; 1(12):776-86.
    View in: PubMed
    Score: 0.004
  28. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Clin Lung Cancer. 2003 Jul; 5(1):40-5.
    View in: PubMed
    Score: 0.004
  29. Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. JAMA. 1983 Apr 08; 249(14):1881-6.
    View in: PubMed
    Score: 0.004
  30. Hormonal therapy for metastatic male breast cancer. Arch Intern Med. 1983 Feb; 143(2):237-40.
    View in: PubMed
    Score: 0.004
  31. Treatment for meningeal carcinomatosis in breast cancer. Cancer. 1982 Jul 15; 50(2):219-22.
    View in: PubMed
    Score: 0.004
  32. Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen. Cancer. 1982 Feb 01; 49(3):413-7.
    View in: PubMed
    Score: 0.004
  33. Systemic therapy of metastatic breast cancer: a review of the current trends. Oncology. 1982; 39(3):140-5.
    View in: PubMed
    Score: 0.003
  34. Doxorubicin, mitolactol (dibromodulcitol), and mitomycin C treatment for patients with metastatic breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone (CMFVP). Cancer Treat Rep. 1981 Jan-Feb; 65(1-2):33-8.
    View in: PubMed
    Score: 0.003
  35. Response to hormonal therapy as a prognostic factor for metastatic breast cancer treated with combination chemotherapy. Cancer. 1980 Aug 01; 46(3):438-45.
    View in: PubMed
    Score: 0.003
  36. The natural history of breast cancer patients with brain metastases. Cancer. 1979 Nov; 44(5):1913-8.
    View in: PubMed
    Score: 0.003
  37. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res. 1979 May; 39(5):1552-62.
    View in: PubMed
    Score: 0.003
  38. Endobronchial metastases in breast carcinoma. West J Med. 1978 Sep; 129(3):177-80.
    View in: PubMed
    Score: 0.003
  39. Prediction of survival by degree of reactivity to BCG in patients with metastatic breast cancer. Dev Biol Stand. 1986; 58 ( Pt A):357-63.
    View in: PubMed
    Score: 0.001
  40. Management of inflammatory carcinoma of the breast. A combined modality approach. Am J Clin Oncol. 1985 Apr; 8(2):134-41.
    View in: PubMed
    Score: 0.001
  41. Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Cancer. 1985 Jan 15; 55(2):341-6.
    View in: PubMed
    Score: 0.001
  42. The management of locally advanced breast cancer: a combined modality approach. Eur J Cancer Clin Oncol. 1984 Nov; 20(11):1353-61.
    View in: PubMed
    Score: 0.001
  43. Phase II evaluation of vinblastine, methotrexate, and calcium leukovorin rescue in patients with refractory metastatic breast cancer. Cancer. 1983 Mar 01; 51(5):769-72.
    View in: PubMed
    Score: 0.001
  44. Multimodal treatment of locoregionally advanced breast cancer. Cancer. 1983 Mar 01; 51(5):763-8.
    View in: PubMed
    Score: 0.001
  45. Estrogen receptor status in inflammatory breast carcinoma. J Surg Oncol. 1982 Sep; 21(1):42-4.
    View in: PubMed
    Score: 0.001
  46. Peptichemio versus melphalan (L-PAM) in advanced breast cancer. Cancer. 1982 May 01; 49(9):1767-70.
    View in: PubMed
    Score: 0.001
  47. Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer. Breast Cancer Res Treat. 1982; 2(2):163-9.
    View in: PubMed
    Score: 0.001
  48. Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion. Cancer Treat Rep. 1981 Sep-Oct; 65(9-10):775-9.
    View in: PubMed
    Score: 0.001
  49. Prognostic value of prechemotherapy skin tests in patients with metastatic breast carcinoma. Cancer. 1981 Mar 15; 47(6):1369-76.
    View in: PubMed
    Score: 0.001
  50. Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer. Cancer Treat Rep. 1980 Feb-Mar; 64(2-3):279-83.
    View in: PubMed
    Score: 0.001
  51. Strategy for evaluation of a new antitumor agent in the treatment of breast cancer. Recent Results Cancer Res. 1980; 70:153-7.
    View in: PubMed
    Score: 0.001
  52. Male breast cancer: a natural history study. Cancer. 1979 Aug; 44(2):748-54.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.